Variant Toll-Like Receptor4 (Asp299Gly and Thr399Ile Alleles) and Toll-Like Receptor2 (Arg753Gln and Arg677Trp Alleles) in Colorectal Cancer
,
Abstract
The innate immune system recognizes the presence of bacterial products through the expression of a family of membrane receptors known as Toll-like receptors (TLRs). Polymorphisms in TLRs have been shown to be associated with increased susceptibility to diseases such as inflammatory bowel disease.
The aim of this study was to determine whether there was a correlation between polymorphisms of TLR4 (Asp299Gly; Thr399Ile) and TLR2 (Arg677Trp; Arg753Gln) genes and risk of colorectal cancer. DNA from 60 colorectal carcinoma patients from 3 major races in Malaysia (22 Malays, 20 Chinese and 18 Indians) and blood from 50 apparently healthy individuals were evaluated. Control group were matched to study group by race and age. The polymorphisms were determined by Polymerase Chain Reaction-Restriction Fragment Length Polymorphism (PCR-RFLP).
Genotyping results showed two out of sixty tumor specimens (3.3%) harbored both variant TLR4 Asp299Gly and Thr399Ile alleles. In contrast, DNA isolated from blood cells of 50 apparently healthy individuals harbored wild type TLR4. In the case of TLR2 Arg753Gln genotyping, all of the fifty normal and 60 tumors were of the wild type genotype. TLR2 Arg677Trp genotyping showed a heterozygous pattern in all samples. However, this may not be a true polymorphism of the TLR2 gene as it is likely due to a variation of a duplicated (pseudogene) region. There was only a low incidence (2/60; 3.3%) of TLR4 polymorphism at the Asp299Gly and Thr399Ile alleles in colorectal cancer patients. All normal and tumor samples harbored the wild type TLR2 Arg753 allele.
Our study suggests that variant TLR4 (Asp299Gly and Thr399Ile alleles) as well as TLR2 (Arg753Gln allele) are not associated with risk of colorectal cancer.
Hawk ET, Linburg PJ, Viner JL. Epidemiology and prevention 1. Hawk ET, Linburg PJ, Viner JL. Epidemiology and prevention of colorectal cancer. Surg Clin North Am 2002; 82(5):905-41
2. Balkwill F, Coussens LM. Cancer: an inflammatory link. Nature 2004; 431(7007):405-6
3. Willett W. The search for the causes of breast and colon cancer. Nature1989; 338(6214):389-94
4. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61(5):759-67
5. Reddy B, Engle A, Katsifis S, Simi B, Bartram HP, Perrino P, et al. Biochemical epidemiology of colon cancer: effect of types of dietary fiber on fecal mutagens, acid, and neutral sterols in healthy subjects. Cancer Res 1989; 49(16):4629-35
6. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420()6917:860-7
7. Robinson SC, Coussens LM. Soluble mediators of inflammation during tumor development. Adv Cancer Res 2005; 93:159-87
8. Seril DN, Lia J, Yang GY, Yang CS. Oxidative stress and ulcerative colitis associated carcinogenesis: studies in humans and animal models. Carcinogenesis 2003; 24(3):353-62
9. Itzkowitz SH, Yio X. Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am J Physiol Gastrointest Liver Physiol 2004; 287(1):G7-17
10. Kelly MG, Alvero AB, Chen R, Silasi DA, Abrahams VM, Chan S, et al. TLR-4 Signaling Promotes Tumor Growth and Paclitaxel Chemoresistance in Ovarian Cancer. Cancer Res 2006; 66(7):3859-68
11. Kopp E, Medzhitov R. Recognition of microbial infection by Toll-like receptors. Curr Opin Immunol 2003; 15(4):396-401
12. Akira S, Akeda K. Toll-like receptor signaling. Nat Immunol 2004; 4(7):499-511
13. De Visser KE, Coussens LM. The interplay between innate and adaptive immunity regulates cancer development. Cancer Immunol Immunother 2005; 54(11):1143-52
14. Takeuchi O, hoshino T, kawai H, sanjo H, takada T, ogawa K, et al. Differential roles of TLR2 and TLR4 in recognition of gram-negative and gram-positive bacterial cell wall components. Immunity 1999; 11(4):443-51
15. Arbour NC, Lorenz E, Schutte BC, Zabner J, Kline JN, Jones M, et al. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet 2000; 25(2):187-91
16. Zheng SL, Augustsson-Bälter K, Chang B, Hedelin M, Li L, Adami HO, et al. Sequence variants of toll-like receptor 4 are associated with prostate cancer risk: results from the Cancer Prostate in Sweden Study. Cancer Res 2004; 64(8):2918-22
17. Chen YC, Giovannucci E, Lazarus R, Kraft P, Ketkar S, Hunter DJ. Sequence variants of Toll-like receptor 4 and susceptibility to prostate cancer. Cancer Res 2005; 65(24):11771-8
18. Achyuta BR, Ghoshalb UC, Moorchung N, Mittal B. Association of Toll-like receptor-4 (Asp299Gly and Thr399Ileu) gene polymorphisms with gastritis and precancerous lesions. Hum Immunol 2007; 68(11):901-7
19. Garza-Gonzalez E, Bosques-Padilla FJ, Mendoza-Ibarra SI, Flores-Gutierrez JP, Maldonado-Garza HJ, Perez-Perez GI. Assessment of the toll-like receptor 4 Asp299gly, thr399Ile and interleukin-8 -251 polymorphisms in the risk for the development of distal gastric cancer. BMC Cancer 2007; 7:70-5
20. Hold GL, Rabkin CS, Chow WH, Smith MG, Gammon MD, Risch HA, et al. A functional polymorphism of toll-like receptor 4 gene increases risk of gastric carcinoma and its precursors. Gastroenterology 2007; 132(3):905-12
21. Weighardt H, Kaiser-Moore S, Vabulas RM, Kirschning CJ, Wagner H, Holzmann B. Cutting edge: Myeloid differentiation factor 88 deficiency improves resistance against sepsis caused by polymicrobial infection. J Immunol 2002; 169(6):2823-7
22. Simpson JL, Grissell TV, Douwes J, Scott RJ, Boyle MJ, Gibson PG. Innate immune activation in neutrophilic asthma and bronchiectasis. Thorax 2007; 62(3):211-8
23. De Kleijn D, Pasterkamp G. Toll-like receptors in cardiovascular diseases. Cardiovasc Res 2003; 60(1):58-67
24. Rock FL, Hardiman G, Timans JC, Kastelein RA, Bazan JF. A family of human receptors structurally related to DrosophilaToll. Proc Natl Acad Sci USA 1998;95(2):588-93
25. Arbour NC, Lorenz E, Schutte BC, Zabner J, Kline J N, Jones M, et al. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet 2000; 25(2):187-91
26. Ferwerda B, McCall MB, Verheijen K, Kullberg BJ, van der Ven AJ, Van der Meer JW, et al. Functional consequences of toll-like receptor 4 polymorphisms. Mol Med 2008; 14(5-6):346-52
27. Kang TJ, Chae GT. Detection of Toll-like receptor 2 (TLR2) mutation in the lepromatous leprosy patients.FEMS Immunol Med Microbiol 2001; 31(1):53-8
28. Boraska Jelavic T, Barisic M, Drmic Hofman I, Boraska V, Vrdoljak E, Peruzovic M, et al. Microsatelite GT polymorphism in the toll-like receptor 2 is associated with colorectal cancer. Clin Genet 2006; 70(2):156-60
29. Cheng PL, Eng HL, Chou MH, You HL, Lin TM. Genetic polymorphisms of viral infection-associated Toll-like receptors in Chinese population. Transl Res 2007; 150(5):311-8
30. Franchimont D, Vermeire S, El Housni H, Pierik M, Van Steen K, Gustot T, et al. Deficient host-bacteria interactions in inflammatory bowel disease? The toll-like receptor (TLR)-4 Asp299gly polymorphism is associated with Crohn’s disease and ulcerative colitis. Gut 2004; 53(7):987-92
32. Gazouli M, Mantzaris G, Kotsinas A, Zacharatos P, Papalambros E, Archimandritis A, et al. Association between polymorphisms in the Toll-like receptor 4, CD14, and CARD15/NOD2 and inflammatory bowel disease in the Greek population. World J Gastroenterol 2005; 11(5):681-5
33. Gree CE, Wheeler CM, Manos M. Sample preparation and PCR amplification from paraffin-embedded tissues. Genome Res 1994; 3(6):113-22
34. Folwaczny M, Glas J, Torok HP, Limbersky O, Folwaczny C. Toll-like receptor (TLR) 2 and 4 mutations in periodontal disease. Clin Exp Immunol 2004; 135(2):330-5
35. Lorenz E, Mira JP, Frees KL, Schwartz DA. Relevance of Mutations in the TLR4 Receptor in Patients with Gram-Negative Septic Shock. Arch Intern Med 2002;162(9):1028-32
36. Yoon HJ, Choi JY, Kim CO, Park YS, Kim MS, Kim YK, et al. Lack of Toll- like receptor 4 and 2 polymorphisms in Korean patients with bacteremia. J Korean Med Sci 2006; 21(6):979-82
37. Kang ES, Lee J. Genotypic analysis of Asp299Gly and Thr399Ile polymorphism of Toll-like receptor 4 in systemic autoimmune diseases of Korean population. Rheumatol Int 2007; 27(9):887-9
38. Liang XH, Cheung W, Heng CK, Wang DY. Absence of the Toll-like receptor 4 gene polymorphisms Asp299Gly and Thr399Ile in Singaporean Chinese. Ther Clin Risk Manag 2005; 1(3):243-6
39. Pandey S, Mittal RD, Srivastava M, Srivastava K, Singh S, Srivastava S, et al. Impact of Toll-like receptors [TLR] 2 (-196 to -174 del) and TLR 4 (Asp299Gly, Thr399Ile) in cervical cancer susceptibility in North Indian women. Gynecol Oncol 2009; 114(3):501-5
40. Malhotra D, Relhan V, Reddy BS, Bamezai R. TLR2 Arg677Trp polymorphism in leprosy: revisited. Hum Genet 2005; 116(5):413-5
41. Nishimura M, Naito S. Tissue-specific mRNA expression profiles of human toll-like receptors and related genes. Biol Pharm Bull 2005; 28(5):886-92
| Files | ||
| Issue | Vol 10, No 2 (2011) | |
| Section | Articles | |
| Keywords | ||
| Colorectal Cancer Polymorphisms Toll like Receptors | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
